Balovaptan

DB14823InvestigationalSmall molecule

Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)).

Mechanism: Pharmacologically active on Vasopressin V1a receptor
Curator reviewed
Formula / weight: C₂₂H₂₄ClN₅O · 409.92 g/mol (avg)
Code names: RG7314

Resolves to

Compound

UNIIRAX5D5AGV6CAS1228088-30-9

Structure

InChIKeyGMPZPHGHNDMRKL-RZDIXWSQSA-NSMILESCN1CC2=NN=C([C@H]3CC[C@@H](CC3)OC3=NC=CC=C3)N2C2=CC=C(Cl)C=C2C1

Targets

P37288AVPR1A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Balovaptan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account